Annals of Oncology 15:613-617, 2004
© 2004 European Society for Medical Oncology
Original Paper |
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome
Received 23 October 2003; revised 19 November 2003; accepted 22 December 2003Background:
The expression of CXCR4 has been implicated in metastatic dissemination in different models of breast cancer and melanoma. In the present study, we evaluated CXCR4 expression in non-small-cell lung cancer (NSCLC) and the relationship between CXCR4 expression and the prognosis of stage I disease.
Patients and methods:
Using immunohistochemical analysis, we retrospectively analyzed CXCR4 expression in specimens from 61 patients with completely resected pathologically confirmed stage I NSCLC for whom clinical follow-up data were available.
Results:
In the present study, we have shown that: CXCR4 is expressed by tumor cells in stage I NSCLC; CXCR4 is located in the nucleus and/or in the cytoplasm of tumor cells; strong nuclear staining was observed in 17 cases (29.8%); patients whose tumors had CXCR4-positive nuclear staining had a significantly longer duration of survival than patients whose tumors had no nuclear expression (P = 0.039, log-rank test). Interestingly, the 5-year metastasis rates were 23.5% and 34.1% in patients with CXCR4-positive and CXCR4-negative nuclear expression, respectively (P = 0.2).
Conclusion:
Strong CXCR4-positive nuclear staining was associated with a significantly better outcome in early-stage NSCLC. The mechanisms underlying this clinically and biologically important finding need to be further explored.
1 SOMPS, Pitié Salpetrière Hospital, Paris; 2 Départment de Médecine, Institut Gustave Roussy, Villejuif; 3 CEA-DSV/DRR/LRO, Fontenay aux Roses Cedex; 4 Laboratoire d‘Immunologie Cellulaire, Faculté de Médecine Pitié-Salpétrière; 5 Avicenne Hospital, Bobigny Cedex, France
Key words: chemokines, CXCR4, immunohistochemistry, lung cancer, prognostic factor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. L. Wagner, E. Hyjek, M. F. Vazquez, D. Meherally, Y. F. Liu, P. A. Chadwick, T. Rengifo, G. L. Sica, J. L. Port, P. C. Lee, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Singh, V. C. Bond, M. Powell, U. P. Singh, H. L. Bumpers, W. E. Grizzle, and J. W. Lillard Jr. CXCR4-gp120-IIIB interactions induce caspase-mediated apoptosis of prostate cancer cells and inhibit tumor growth Mol. Cancer Ther., January 1, 2009; 8(1): 178 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Begley, J. W. MacDonald, M. L. Day, and J. A. Macoska CXCL12 Activates a Robust Transcriptional Response in Human Prostate Epithelial Cells J. Biol. Chem., September 14, 2007; 282(37): 26767 - 26774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Cabioglu, Y Gong, R Islam, K. Broglio, N Sneige, A Sahin, A. Gonzalez-Angulo, P Morandi, C Bucana, G. Hortobagyi, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer Ann. Onc., June 1, 2007; 18(6): 1021 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tsoli, P. K Tsantoulis, A. Papalambros, B. Perunovic, D. England, D. A Rawlands, G. M Reynolds, D. Vlachodimitropoulos, S. L Morgan, C. A Spiliopoulou, et al. Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer J. Clin. Pathol., March 1, 2007; 60(3): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Wald, U. Izhar, G. Amir, S. Avniel, Y. Bar-Shavit, H. Wald, I. D. Weiss, E. Galun, and A. Peled CD4+CXCR4highCD69+ T Cells Accumulate in Lung Adenocarcinoma J. Immunol., November 15, 2006; 177(10): 6983 - 6990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andre, N. Cabioglu, H. Assi, J. C. Sabourin, S. Delaloge, A. Sahin, K. Broglio, J. P. Spano, C. Combadiere, C. Bucana, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer Ann. Onc., June 1, 2006; 17(6): 945 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Scala, P. Giuliano, P. A. Ascierto, C. Ierano, R. Franco, M. Napolitano, A. Ottaiano, M. L. Lombardi, M. Luongo, E. Simeone, et al. Human Melanoma Metastases Express Functional CXCR4 Clin. Cancer Res., April 15, 2006; 12(8): 2427 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Kaifi, E. F. Yekebas, P. Schurr, D. Obonyo, R. Wachowiak, P. Busch, A. Heinecke, K. Pantel, and J. R. Izbicki Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer J Natl Cancer Inst, December 21, 2005; 97(24): 1840 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Cabioglu, M. S. Yazici, B. Arun, K. R. Broglio, G. N. Hortobagyi, J. E. Price, and A. Sahin CCR7 and CXCR4 as Novel Biomarkers Predicting Axillary Lymph Node Metastasis in T1 Breast Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5686 - 5693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zagzag, B. Krishnamachary, H. Yee, H. Okuyama, L. Chiriboga, M. A. Ali, J. Melamed, and G. L. Semenza Stromal Cell-Derived Factor-1{alpha} and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor Cancer Res., July 15, 2005; 65(14): 6178 - 6188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kim, H. Takeuchi, S. T. Lam, R. R. Turner, H.-J. Wang, C. Kuo, L. Foshag, A. J. Bilchik, and D. S.B. Hoon Chemokine Receptor CXCR4 Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival J. Clin. Oncol., April 20, 2005; 23(12): 2744 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Katayama, T. Ogino, N. Bandoh, S. Nonaka, and Y. Harabuchi Expression of CXCR4 and Its Down-Regulation by IFN-{gamma} in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., April 15, 2005; 11(8): 2937 - 2946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Schimanski, S. Schwald, N. Simiantonaki, C. Jayasinghe, U. Gonner, V. Wilsberg, T. Junginger, M. R. Berger, P. R. Galle, and M. Moehler Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1743 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Scala, A. Ottaiano, P. A. Ascierto, M. Cavalli, E. Simeone, P. Giuliano, M. Napolitano, R. Franco, G. Botti, and G. Castello Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma Clin. Cancer Res., March 1, 2005; 11(5): 1835 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Slimane, F. Andre, S. Delaloge, A. Dunant, A. Perez, J. Grenier, C. Massard, and M. Spielmann Risk factors for brain relapse in patients with metastatic breast cancer Ann. Onc., November 1, 2004; 15(11): 1640 - 1644. [Abstract] [Full Text] [PDF]
|
|